|1.||Uttley, Lesley: 3 articles (11/2014 - 12/2013)|
|2.||Tappenden, Paul: 3 articles (11/2014 - 12/2013)|
|3.||Falagas, Matthew E: 3 articles (01/2011 - 12/2005)|
|4.||Harnan, Sue: 2 articles (02/2014 - 12/2013)|
|5.||Walshaw, Martin: 2 articles (02/2014 - 12/2013)|
|6.||Brownlee, Keith: 2 articles (02/2014 - 12/2013)|
|7.||Markantonis, Sophia L: 2 articles (11/2012 - 01/2011)|
|8.||Thamlikitkul, Visanu: 2 articles (12/2010 - 09/2007)|
|9.||Biller, Julie A: 1 article (11/2015)|
|10.||Kim, Kyung Soo: 1 article (06/2015)|
06/01/2010 - "Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug-resistant P. "
06/01/2015 - "Colistimethate sodium (CMS) is increasingly used to treat multidrug-resistant Gram-negative bacilli infections. "
01/01/2015 - "aeruginosa lung infection and the impact of systemic therapy with colistimethate sodium (CMS). "
01/01/2015 - "Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium."
01/01/2014 - "This article reviews the available evidence to reflect on the place of colistimethate sodium in the therapy of chronic pulmonary infection in CF. "
|2.||Cystic Fibrosis (Mucoviscidosis)
11/01/2007 - "Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic fibrosis."
04/01/2013 - "Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study."
05/01/2014 - "In contrast, cystic fibrosis was found to be a protective factor in patients who received colistimethate (OR, 0.03; 95% CI, 0.001 to 0.79; P = 0.04). "
02/01/2009 - "Seven children without cystic fibrosis (mean age 7.7 years; 2 female), admitted to the intensive care unit of a tertiary-care pediatric hospital in Athens, Greece, were identified to have received intravenous colistimethate during October 2004 to May 2008. "
01/01/2015 - "Infections of the respiratory tract with Pseudomonas aeruginosa in cystic fibrosis patients are frequently treated with colistimethate sodium (CMS). "
|4.||Critical Illness (Critically Ill)
11/01/2012 - "Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients."
02/01/2009 - "Although the small number of included cases precludes any firm conclusions, our study suggests that colistimethate may have a role for the treatment of infections caused by MDR Gram-negative bacteria in critically ill pediatric patients."
02/01/2009 - "We present a case series of critically ill pediatric patients without cystic fibrosis who received intravenous colistimethate treatment. "
08/01/2013 - "Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii."
01/01/2011 - "Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium."
|5.||Urinary Tract Infections (Urinary Tract Infection)
01/01/1970 - "Intravenous sodium colistimethate therapy of urinary-tract infections: pharmacological and bacteriological studies."
06/01/1967 - "Intravenous administration of sodium colistimethate in urinary tract infections."
07/24/1965 - "Colistimethate sodium (Coly-Mycin) was used in the treatment of 17 patients: 13 had urinary tract infections (two of these had positive blood cultures), three had respiratory tract infections, and one patient had both urinary and respiratory tract infections. "
|3.||Anti-Bacterial Agents (Antibiotics)
|7.||Polymyxin B (Aerosporin)
|1.||Dry Powder Inhalers
|3.||Transplantation (Transplant Recipients)
|4.||Artificial Respiration (Mechanical Ventilation)
|5.||Drug Therapy (Chemotherapy)